CD2314（Cat No.:I005906）is a selective inhibitor targeting specific protein kinases involved in cell signaling pathways that regulate cell proliferation, survival, and apoptosis. It has shown potential in inhibiting the growth of cancer cells, particularly in tumors with abnormal kinase activity. CD2314 is being studied for its possible therapeutic applications in oncology, especially for cancers resistant to conventional treatments. Early-stage research indicates that it could help overcome resistance mechanisms, enhancing the effectiveness of other therapies. However, further preclinical and clinical studies are required to evaluate its safety, efficacy, and potential for widespread use in cancer treatment.